Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

SAB Biotherapeutics (SABSW) Non-Current Assets (2020 - 2025)

SAB Biotherapeutics' Non-Current Assets history spans 6 years, with the latest figure at $71.8 million for Q4 2025.

  • For Q4 2025, Non-Current Assets rose 251.7% year-over-year to $71.8 million; the TTM value through Dec 2025 reached $184.6 million, up 108.81%, while the annual FY2025 figure was $71.8 million, 251.7% up from the prior year.
  • Non-Current Assets reached $71.8 million in Q4 2025 per SABSW's latest filing, up from $70.2 million in the prior quarter.
  • In the past five years, Non-Current Assets ranged from a high of $116.2 million in Q3 2021 to a low of $20.4 million in Q4 2024.
  • Average Non-Current Assets over 5 years is $43.9 million, with a median of $28.2 million recorded in 2022.
  • Peak YoY movement for Non-Current Assets: crashed 73.89% in 2022, then skyrocketed 251.7% in 2025.
  • A 5-year view of Non-Current Assets shows it stood at $30.9 million in 2021, then dropped by 6.92% to $28.8 million in 2022, then dropped by 13.1% to $25.0 million in 2023, then fell by 18.5% to $20.4 million in 2024, then surged by 251.7% to $71.8 million in 2025.
  • Per Business Quant, the three most recent readings for SABSW's Non-Current Assets are $71.8 million (Q4 2025), $70.2 million (Q3 2025), and $20.8 million (Q2 2025).